Favorable Response to CD34+ Cell Therapy Is Associated with a Decrease of Galectin-3 Levels in Patients with Chronic Heart Failure

<div>Comparison of plasma galectin-3 baseline (spotted bars) and follow-up (checkered bars) values found no differences when compared in the entire patient cohort and separately in patients with ICMP and DCMP.</div>

Disease Markers

fig1

Figure 1

Figure 1: Favorable Response to CD34+ Cell Therapy Is Associated with a Decrease of Galectin-3 Levels in Patients with Chronic Heart Failure 